Fulcrum Therapeutics, Inc.

NASDAQ:FULC

Biotechnology

Healthcare
$3.72 +1.71%

+$0.06 today

Market cap
$284.14M
Beta
2.92
P/E (TTM)
-3.6
EPS (TTM)
-$1.00
52W Low $2.83High $15.74

Volume 0.63M

Average 1.78M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$60.06M

FY 2025 · Annual

Investing Cash Flow

$30.72M

FY 2025 · Annual

-4.7% YoY

Financing Cash Flow

$168.67M

FY 2025 · Annual

+6042.3% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(80.85M)(109.87M)(97.34M)(9.73M)(74.88M)
Depreciation & Amortization2.52M2.41M2.17M1.59M1.39M
Deferred Income Tax00000
Stock-Based Compensation11.07M13.35M14.8M14.55M12.47M
Change in Working Capital(11.89M)(3.09M)(4.61M)(4.25M)3.91M
Accounts Receivables(500K)2.5M(308K)(1.56M)2.1M
Inventory1.25M0000
Accounts Payables973K(1.18M)(853K)(1.59M)428K
Other Working Capital(13.61M)(4.42M)(3.45M)(1.1M)1.39M
Other Non-Cash Items673K152K(5.99M)(4.39M)(2.95M)
Operating Cash Flow(78.48M)(97.05M)(90.97M)(2.22M)(60.07M)
Capital Expenditures(1.71M)(1.96M)(508K)(278K)(314K)
Acquisitions (Net)127.96M(14.38M)000
Purchases of Investments(216.23M)(151.15M)(194.89M)(178.59M)(180.22M)
Sales of Investments88.28M165.53M158.71M211.1M211.25M
Other Investing Activities(127.96M)14.38M000
Investing Cash Flow(129.67M)12.41M(36.69M)32.23M30.72M
Debt Repayment(18K)0000
Common Stock Issued182.86M80.8M117.35M2.75M168.67M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.67M3.52M777K00
Financing Cash Flow186.51M84.32M118.12M2.75M168.67M
Effect of Forex Changes00000
Net Change in Cash(21.64M)(314K)(9.54M)32.76M139.32M
Free Cash Flow(80.19M)(99.01M)(91.47M)(2.5M)(60.38M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$74.9M
+ D&A$1.4M
+ Stock-Based Comp$12.5M
+ Deferred Tax$0
+ Working Capital$3.9M
- Other Non-Cash-$3.0M
= Operating Cash Flow-$60.1M
- Capex-$314.0K
= Free Cash Flow-$60.4M

Analysis

FY2025 free cash flow is -$60.4M. FCF conversion is 80.6% of net income. Operating cash flow was -$60.1M, with capex of -$314.0K. The largest bridge item is Stock-Based Comp at $12.5M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 13, 2026
SC 13G/ASC 13G/A filingNov 13, 2026
10-QQuarterly reportNov 12, 2026
8-KCurrent reportNov 12, 2026
425425 filingNov 12, 2026

Does FULC generate free cash flow?

Fulcrum Therapeutics, Inc. (FULC) generated -$60.38M of free cash flow in fiscal 2025.

How much operating cash flow does FULC produce?

Operating cash flow was -$60.06M, before capital expenditures of $314,000.00.